Maple Capital Management buys $6.5 Million stake in Eli Lilly and Co (LLY)

Eli Lilly and Co (LLY) : Maple Capital Management scooped up 11,926 additional shares in Eli Lilly and Co during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 13, 2016. The investment management firm now holds a total of 85,652 shares of Eli Lilly and Co which is valued at $6.5 Million.Eli Lilly and Co makes up approximately 2.43% of Maple Capital Management’s portfolio.

Other Hedge Funds, Including , Roosevelt Investment Group Inc reduced its stake in LLY by selling 53,292 shares or 94.76% in the most recent quarter. The Hedge Fund company now holds 2,946 shares of LLY which is valued at $224,868. Eli Lilly and Co makes up approx 0.02% of Roosevelt Investment Group Inc’s portfolio.New Mexico Educational Retirement Board boosted its stake in LLY in the latest quarter, The investment management firm added 2,100 additional shares and now holds a total of 107,994 shares of Eli Lilly and Co which is valued at $8.2 Million. Eli Lilly and Co makes up approx 0.40% of New Mexico Educational Retirement Board’s portfolio.Amalgamated Bank boosted its stake in LLY in the latest quarter, The investment management firm added 9,240 additional shares and now holds a total of 38,853 shares of Eli Lilly and Co which is valued at $3 Million. Eli Lilly and Co makes up approx 0.29% of Amalgamated Bank’s portfolio.Marble Harbor Investment Counsel boosted its stake in LLY in the latest quarter, The investment management firm added 80 additional shares and now holds a total of 5,980 shares of Eli Lilly and Co which is valued at $446,108. Eli Lilly and Co makes up approx 0.11% of Marble Harbor Investment Counsel’s portfolio.Rhumbline Advisers boosted its stake in LLY in the latest quarter, The investment management firm added 39,340 additional shares and now holds a total of 1,340,962 shares of Eli Lilly and Co which is valued at $100 Million. Eli Lilly and Co makes up approx 0.31% of Rhumbline Advisers’s portfolio.

Eli Lilly and Co closed down -0.45 points or -0.60% at $74.54 with 46,21,719 shares getting traded on Wednesday. Post opening the session at $75.49, the shares hit an intraday low of $74.45 and an intraday high of $75.5 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

On the company’s financial health, Eli Lilly and Co reported $0.83 EPS for the quarter, missing the analyst consensus estimate by $ -0.02 based on the information available during the earnings call on Apr 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $4865.10 million for the quarter, compared to analysts expectations of $4829.37 million. The company’s revenue was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.87 EPS.

Many Wall Street Analysts have commented on Eli Lilly and Co. Company shares were Reiterated by Leerink Partners on May 2, 2016 to “Outperform”, Firm has raised the Price Target to $ 101 from a previous price target of $96 .Societe Generale Initiated Eli Lilly and Co on Apr 6, 2016 to “Hold”, Price Target of the shares are set at $78.

Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.

Leave a Reply

Eli Lilly and Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Eli Lilly and Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.